drugset
Drugs / Eicosapentaenoic acid-ethyl
last change Jan 2011 re-read 3 minutes ago

Eicosapentaenoic acid-ethyl

also known as EPA-E · EPA
Developed for
hypertriglyceridemia
Investigated by
Takeda

Trials 1

today NCT01350973 · Ph 3
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial · 1 met primary
Phase 3 NCT01350973 Nov 2009 → Dec 2010 hypertriglyceridemia Takeda Completed Met primary
Comparator or background therapy1 trial
Phase 3 NCT01350999 Comparator Nov 2009 → Jan 2011 hypertriglyceridemia Takeda Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Eicosapentaenoic acid-ethyl ClinicalTrials.gov intervention name — accepted as the source's own label NCT01350973 ↗
1

NCT01350999 ↗
Known as EPA “Eicosapentaenoic acid-ethyl (EPA)” NCT01350999 ↗
Known as EPA-E “Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.” NCT01350973 ↗
1

“ethyl eicosapentaenoate (EPA-E)” NCT01350999 ↗
Route Oral “EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.” NCT01350973 ↗